As of December 31, 2024, Argenx (ARGX) had approximately $3.4B in cash, cash equivalents and current financial assets.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $761 from $717 at BofA
- Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
- Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment
- Argenx announces Japan MHLW approval for Vyvdura for CIDP
- Argenx price target raised to $723 from $639 at Wells Fargo